In summary, we have designed and prepared the CD163 monoclonal antibody modified doxorubicin-polymer prodrug nanoparticles, mAb-CD163-PDNPs, for actively targeting tumor-associated macrophages (TAMs). This evidence concerns the gene CD163 and neoplasm.